Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1468230 | 0.94 | — | — | |
| SCHEMBL5163167 | 0.94 | — | — | |
| SCHEMBL3547379 | 0.94 | — | — | |
| SCHEMBL2915330 | 0.82 | — | — | |
| SCHEMBL4803959 | 0.79 | EPHX1 (0.41) | RAB9ASMN1; SMN2 | |
| SCHEMBL863279 | 0.76 | — | — | |
| SCHEMBL1219868 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL3362858 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL2918633 | 0.75 | POLB (0.36) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL2917294 | 0.73 | CHRNB2 (0.38) | SMN1; SMN2CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | claimed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | claimed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | claimed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | claimed |
| EP-1754477-A2 | Hydroxamic acid derivatives as antibacterials | Vernalis (Oxford) Limited (GB) | 2007-02-21 | — | — | EP | claimed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1079819-A1 | HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-03-07 | — | — | EP | claimed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | claimed |
| US-6022873-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-02-08 | — | — | US | claimed |
| WO-1999059568-A1 | HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| EP-0944597-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | claimed |
| EP-0934292-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-11 | — | — | EP | claimed |
| WO-1998023588-A9 | METALLOPROTEINASE INHIBITORS | — | 1998-09-17 | — | — | WO | claimed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1998017655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-04-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | GRM4 2920/4885HDAC8 2710/4885HDAC6 492/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | GRM4 2209/4885HDAC8 917/4885HDAC6 394/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GRM4 4610/4885HDAC8 1078/4885HDAC6 364/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | GRM4 2072/4885HDAC8 1130/4885HDAC6 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.